Pro
tocols should be in line with OECD Guideline 471 (Salmonella typhimuri
um Reverse Mutation Test), 472 (Escherichia coli Reverse Muta
tion Test), 473 (in vitro Mammalian Chromosoma
l Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Ma
mmalian Bone Marrow Chromosomal Aberratio ...[+++]n Test), 476 (in vitro Mammalian Cell Gene Mutation Test) or 482 (Unscheduled DNA Synthesis in Mammalian Cells in vitro), as well as other relevant OECD Guidelines for in vitro and in vivo assays.Die Verfahren sollten einer der folgenden OECD-Leitlinien sowie sonstigen einschlägigen OEC
D-Leitlinien für In-vitro- und In-vivo-Tests entsprechen: 471 (Salmonella typhimuri
um Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation Test), 473
(In vitro Mammalian Chromosome Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Mammalian Bon
e Marrow Chromosome Aberration ...[+++] Test), 476 (In vitro Mammalian Cell Gene Mutation Test) oder 482 (Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA Synthesis in Mammalian Cells in vitro).